GGrantIndex
← Leaderboards

Timothy W Schacker

University Of Minnesota Twin Cities

$31,962,448
Attributed
$32,851,924
Total exposure
23
Grants
17
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.7M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$44,972,188 · 24

By mechanism

P01$17,244,727 · 4
R01$14,807,171 · 6
U01$8,401,871 · 2
U19$2,838,960 · 1
K24$657,266 · 1
R56$579,431 · 1

Top collaborators

Most similar at University Of Minnesota Twin Cities

Same institution · by research overlap

Others in their field

Top investigators on “Hiv Infections

Research focus

Hiv InfectionsLymph NodesInfectionTissuesCd4 Positive T LymphocytesLymphoid TissueCellsGut Associated Lymphoid TissueT-LymphocyteImmuneChronicAntiretroviral TherapyReconstitutionAnatomyPharmaceutical PreparationsClinical ResearchImmune ResponseAntigensStructureCollagenArchitectureResearch PersonnelInflammatoryPhenotype

Grant awards (77)

HIV Reservoir Dynamics Associated with Metabolic Complications of HIV Infection$1,778,953
R01 · FY2025 · DK · contact PI
Investigation of persistent HIV immune stimulation in lymphoid tissues during therapy as a cause of sustained immune activation$735,152
R01 · FY2024 · AI · contact PI
Investigation of persistent HIV immune stimulation in lymphoid tissues during therapy as a cause of sustained immune activation$741,498
R01 · FY2023 · AI · contact PI
The effect of inflammation and damage to lymph node structures on durable protective immunity following vaccination$649,719
U01 · FY2023 · AI · contact PI
Investigation of persistent HIV immune stimulation in lymphoid tissues during therapy as a cause of sustained immune activation$747,958
R01 · FY2022 · AI · contact PI
The effect of inflammation and damage to lymph node structures on durable protective immunity following vaccination$653,365
U01 · FY2022 · AI · contact PI
Investigation of persistent HIV immune stimulation in lymphoid tissues during therapy as a cause of sustained immune activation$707,925
R01 · FY2021 · AI · contact PI
The effect of inflammation and damage to lymph node structures on durable protective immunity following vaccination$601,902
U01 · FY2021 · AI · contact PI
Investigation of persistent HIV immune stimulation in lymphoid tissues during therapy as a cause of sustained immune activation$747,348
R01 · FY2020 · AI · contact PI
Reservoir Dynamics in Patients Treated in Very Early Acute HIV Infection$644,569
R01 · FY2020 · AI · contact PI
The effect of inflammation and damage to lymph node structures on durable protective immunity following vaccination$604,933
U01 · FY2020 · AI · contact PI
Reservoir Dynamics in Patients Treated in Very Early Acute HIV Infection$627,240
R01 · FY2019 · AI · contact PI
The effect of inflammation and damage to lymph node structures on durable protective immunity following vaccination$616,774
U01 · FY2019 · AI · contact PI
Reservoir Dynamics in Patients Treated in Very Early Acute HIV Infection$634,184
R01 · FY2018 · AI · contact PI
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV$990,702
U01 · FY2017 · AI · contact PI
Reservoir Dynamics in Patients Treated in Very Early Acute HIV Infection$641,030
R01 · FY2017 · AI · contact PI
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV$1,070,498
U01 · FY2016 · AI · contact PI
Reservoir Dynamics in Patients Treated in Very Early Acute HIV Infection$654,285
R01 · FY2016 · AI · contact PI
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV$1,060,377
U01 · FY2015 · AI · contact PI
Tissue Analysis$502,578
U19 · FY2015 · AI · contact PI
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV$1,117,257
U01 · FY2014 · AI · contact PI
Antifibrotic Therapy to Improve Immune reconstitution in HIV$610,166
R01 · FY2014 · AI · contact PI
Tissue Analysis$511,207
U19 · FY2014 · AI · contact PI
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV$1,036,344
U01 · FY2013 · AI · contact PI
Tissue Analysis$692,794
U19 · FY2013 · AI · contact PI
Antifibrotic Therapy to Improve Immune reconstitution in HIV$676,037
R01 · FY2013 · AI · contact PI
A Compartmental Analysis of HIV Reservoirs and Immune Reconstitution$2,069,875
P01 · FY2012 · AI · contact PI
Tissue Analysis$736,484
U19 · FY2012 · AI · contact PI
Antifibrotic Therapy to Improve Immune reconstitution in HIV$692,430
R01 · FY2012 · AI · contact PI
Clinical$524,085
P01 · FY2012 · AI · contact PI
Consequence of Cryptic Replication on Immune Function$267,522
P01 · FY2012 · AI · contact PI
Administration$166,043
P01 · FY2012 · AI · contact PI
A Compartmental Analysis of HIV Reservoirs and Immune Reconstitution$2,410,780
P01 · FY2011 · AI · contact PI
Antifibrotic Therapy to Improve Immune reconstitution in HIV$781,254
R01 · FY2011 · AI · contact PI
Clinical$479,973
P01 · FY2011 · AI · contact PI
Tissue Analysis$395,897
U19 · FY2011 · AI · contact PI
Consequence of Cryptic Replication on Immune Function$363,859
P01 · FY2011 · AI · contact PI
Administration$233,928
P01 · FY2011 · AI · contact PI
A Compartmental Analysis of HIV Reservoirs and Immune Reconstitution$2,425,674
P01 · FY2010 · AI · contact PI
Administration$436,951
P01 · FY2010 · AI · contact PI
Clinical$309,229
P01 · FY2010 · AI · contact PI
Consequence of Cryptic Replication on Immune Function$222,999
P01 · FY2010 · AI · contact PI
A Compartmental Analysis of HIV Reservoirs and Immune Reconstitution$196,882
P01 · FY2010 · AI · contact PI
A Compartmental Analysis of HIV Reservoirs and Immune Reconstitution$2,555,145
P01 · FY2009 · AI · contact PI
Administration$484,788
P01 · FY2009 · AI · contact PI
Clinical$303,636
P01 · FY2009 · AI · contact PI
Consequence of Cryptic Replication on Immune Function$222,035
P01 · FY2009 · AI · contact PI
A Compartmental Analysis of HIV Reservoirs and Immune Reconstitution$2,461,908
P01 · FY2008 · AI · contact PI
Lymph Node Inflammation and Fibrosis as a Mechanism of CD4 Loss in HIV$579,431
R56 · FY2008 · AI · contact PI
Consequence of Cryptic Replication on Immune Function$484,297
P01 · FY2008 · AI · contact PI
Clinical$374,333
P01 · FY2008 · AI · contact PI
Administration$250,785
P01 · FY2008 · AI · contact PI
CLINICAL TRIAL: CHANGES IN LYMPHOCYTE POPULATIONS AND ARCHITECTURE BEFORE AND DU$28,882
M01 · FY2008 · RR · contact PI
Damage to the Lymphoid Niche & Timing of HIV Therapy$461,905
R01 · FY2007 · AI · contact PI
Pathogenesis of HIV Induced Lymphoid Tissue Inflammation$138,011
K24 · FY2007 · AI · contact PI
CHANGES IN LYMPHOCYTE POPULATIONS AND ARCHITECTURE BEFORE AND DURING HIV-1 THERA$89,522
M01 · FY2007 · RR · contact PI
Damage to the Lymphoid Niche & Timing of HIV Therapy$482,607
R01 · FY2006 · AI · contact PI
Pathogenesis of HIV Induced Lymphoid Tissue Inflammation$134,778
K24 · FY2006 · AI · contact PI
CHANGES IN LYMPHOCYTE POPULATIONS AND ARCHITECTURE BEFORE AND DURING HIV-1 THERA$117,140
M01 · FY2006 · RR · contact PI
PILOT STUDY OF GLEEVEC THERAPY ON HIV-1 ASSOCIATED LYMPHOID FIBROSIS$15,673
M01 · FY2006 · RR · contact PI
Damage to the Lymphoid Niche &Timing of HIV Therapy$507,575
R01 · FY2005 · AI
Pathogenesis of HIV Induced Lymphoid Tissue Inflammation$131,744
K24 · FY2005 · AI
CHANGES IN LYMPHOCYTE POPULATIONS AND ARCHITECTURE BEFORE AND DURING HIV-1 THERA$80,873
M01 · FY2005 · RR
PILOT STUDY OF GLEEVEC THERAPY ON HIV-1 ASSOCIATED LYMPHOID FIBROSIS$18,381
M01 · FY2005 · RR
Damage to the Lymphoid Niche &Timing of HIV Therapy$661,455
R01 · FY2004 · AI
Pathogenesis of HIV Induced Lymphoid Tissue Inflammation$128,590
K24 · FY2004 · AI
A Protocol to Study the Kinetics of HIV Replication in Cellular Mechanisms Suppo$83,639
M01 · FY2004 · RR
CHANGES IN LYMPHOCYTE POPULATIONS AND ARCHITECTURE BEFORE AND DURING HIV-1 THERA$8,652
M01 · FY2004 · RR
Damage to the Lymphoid Niche &Timing of HIV Therapy$326,649
R01 · FY2003 · AI
Pathogenesis of HIV Induced Lymphoid Tissue Inflammation$124,143
K24 · FY2003 · AI
EPIDEMIOLOGY/MOLECULAR VIROLOGY OF ORAL HIV TRANSMISSION$323,338
R01 · FY2002 · DE
EPIDEMIOLOGY/ MOLECULAR VIROLOGY OF ORAL HIV TRANSMISSIO$0
M01 · FY2002 · RR
EPIDEMIOLOGY/ MOLECULAR VIROLOGY OF ORAL HIV TRANSMISSIO$0
M01 · FY2002 · RR
EPIDEMIOLOGY/MOLECULAR VIROLOGY OF ORAL HIV TRANSMISSION$315,574
R01 · FY2001 · DE
EPIDEMIOLOGY/ MOLECULAR VIROLOGY OF ORAL HIV TRANSMISSIO$0
M01 · FY2001 · RR
EPIDEMIOLOGY/MOLECULAR VIROLOGY OF ORAL HIV TRANSMISSION$308,039
R01 · FY2000 · DE
EPIDEMIOLOGY/ MOLECULAR VIROLOGY OF ORAL HIV TRANSMISSIO$0
M01 · FY2000 · RR